<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03335761</url>
  </required_header>
  <id_info>
    <org_study_id>MDT17030</org_study_id>
    <nct_id>NCT03335761</nct_id>
  </id_info>
  <brief_title>InterStim® Amplitude Study</brief_title>
  <official_title>InterStim® Amplitude Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedtronicNeuro</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedtronicNeuro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This feasibility study will explore the effects of three different InterStim amplitude
      settings on overactive bladder symptoms (OAB).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize effect on Urinary Urge Incontinence</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline in urinary urge incontinence (UUI) episodes per day at 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize effect on Quality of Life (QoL)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline on QoL using ICIQ-OAB QOL at 12 weeks. (Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002;11(6):563-574.)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Urinary Urge Incontinence</condition>
  <arm_group>
    <arm_group_label>Amplitude Setting #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>InterStim Therapy will be set to amplitude parameter #1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amplitude Setting #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>InterStim Therapy will be set to amplitude parameter #2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amplitude Setting #3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>InterStim Therapy will be set to amplitude parameter #3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InterStim Therapy</intervention_name>
    <description>Device Programming</description>
    <arm_group_label>Amplitude Setting #1</arm_group_label>
    <arm_group_label>Amplitude Setting #2</arm_group_label>
    <arm_group_label>Amplitude Setting #3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Primary diagnosis of urinary urge incontinence (UUI) as demonstrated on a 3‐day
             baseline voiding diary demonstrating at least 3 UUI episodes

          2. Female subjects 18 years of age or older

          3. Candidate for InterStim Lead Placement

          4. Willing and able to accurately complete voiding diaries, questionnaires, attend
             visits, and comply with the study protocol (which includes maintenance of InterStim II
             programming settings over the course of the study)

          5. Willing and able to provide signed and dated informed consent

          6. Willing to maintain current regimen (dosage and frequency) of any overactive bladder
             (OAB) medication

        Exclusion Criteria:

          1. Have neurological conditions such as multiple sclerosis, clinically significant
             peripheral neuropathy or spinal cord injury

          2. History of diabetes unless the diabetes is well‐controlled through diet and/or
             medications

          3. Symptomatic urinary tract infection (UTI)

          4. Have primary stress incontinence or mixed incontinence where the stress component
             overrides the urge component

          5. Treatment of urinary symptoms with botulinum toxin in the past 9 months or any plan to
             have botulinum toxin treatment during the study

          6. Implanted with a neurostimulator, pacemaker, or defibrillator

          7. Have knowledge of planned MRIs, diathermy, microwave exposure, high output ultrasonic
             exposure, or radio frequency (RF) energy exposure not included within the scanning
             conditions provided with the MRI Guidelines for InterStim Therapy

          8. Women who are pregnant or planning to become pregnant

          9. Characteristics indicating a poor understanding of the study or characteristics that
             indicate the subject may have poor compliance with the study protocol requirements.

         10. Currently enrolled or planning to enroll in a potentially confounding clinical study
             during the course of the study (co-enrollment in concurrent studies is only allowed
             when documented pre‐approval is obtained from the Medtronic study manager (or
             designee).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elizabeth Michaud</last_name>
    <phone>1 (800) 633-8766</phone>
    <email>beth.m.michaud@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pinellas Urology</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Swan</last_name>
      <phone>727-381-8667</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urologic Research &amp; Consulting</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>201-510-3178</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanford Research</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Benson, MD</last_name>
      <phone>605-328-1368</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chattanooga Hamilton County Hospital Authority d/b/a Erlanger Health System</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>423-778-3900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Urology Associates</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1 (416) 979-9000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust - University College Hospital</name>
      <address>
        <city>London</city>
        <zip>W1G 8PH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>44 20 3456 7898</phone>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urinary</keyword>
  <keyword>Incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence, Urge</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

